|
Immunizations
 2010 Kansas Immunization Conference
Click here for full brochure and registration form
AAP Policy Statement Update – PCV13 recommendations
The AAP has updated their policy on prevention of infections from Streptococcus pneumoniae in infants and children. Recommendations include:
- Infants and children who have started the pneumococcal vaccine series with PCV7 should complete the series with PCV13 unless PCV7 is the only vaccine available.
- A single supplemental dose of PCV13 is recommended for all children ages 14-59 months who have already completed the PCV7 series. PCV13 should be given at least 8 weeks after the last dose of PCV7.
- PCV13 is recommended for children 60 through 71 months of age who have underlying medical conditions that increase their risk of pneumococcal disease or complications, whereas PCV7 was recommended for children at increased risk up to age 59 months
- A single does of PCV13 may be administered to children ages 6-18 years who are at increased risk for invasive pneumococcal disease, even through the vaccine is not licensed for children 6 years of age and older.
To review the entire policy statement click on recommendations for use of the newly licensed 13-valent pneumococcal polysaccharide protein-conjugate vaccine (Prevnar 13[PCV13], Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.
Click here for more information on recommendations
Posted on 7/5/2010
Protect Tomorrow is a national education awareness campaign that reminds parents of the importance of childhood immunizations!
For more information visit:
http://www.aap.org/protecttomorrow/
Novel H1N1 Influenza Vaccine information from CDC
CDC’s Advisory Committee on Immunization Practices (ACIP) met on July 29, 2009 to make recommendations on who should receive the new H1N1 vaccine when it becomes available, and to determine which groups of people should be prioritized if the vaccine is initially available in limited quantities.
The committee recommended that initial vaccination efforts focus on five key populations:
- All people 6 months through 24 years of age
- People who live with or care for children younger than 6 months of age
- All pregnant women
- Healthcare and emergency services personnel
- People aged 25 through 64 years who have health conditions associated with higher risk of medical complications from influenza.
Together, these key populations equal 159 million. Once the demand for vaccine for these prioritized groups has been met at the local level, programs and providers should begin vaccinating everyone from the ages of 25 through 64 years.
If vaccine is available in insufficient amounts for the initial priority groups, the following groups would be prioritized:
- Pregnant women
- People who live with or care for children younger than 6 months of age
- Healthcare and emergency service personnel with direct patient contact
- Children 6 months through 4 years of age
- Children 5 through 18 years of age who have chronic medical conditions.
Novel H1N1 vaccine supply and availability is projected to increase quickly over time, and vaccine should not be kept in reserve for later administration of the second dose.
The novel H1N1 vaccine is not intended to replace the seasonal flu vaccine – it is intended to be used along-side seasonal flu vaccine to protect people. It is anticipated that both vaccines can be administered on the same day.
There are many steps involved with producing a vaccine and we are committed to going forward with NIH, FDA, BARDA an the manufacturers of influenza vaccines, to see about developing full scale vaccine production. If things progress to full scale production, vaccine may be available as early as mid-October. The novel H1N1 vaccine will be made using the same process and facilities that are used to make the currently licensed seasonal influenza vaccines.
We are concerned with protecting our nation’s children from vaccine-preventable diseases like influenza and preventing any possible adverse events from vaccines. We expect that H1N1 will be available inn multiple formulations, including a formulation that does not contain the preservative thimerosal.
Posted on 8/10/2009
New Alerts
Vaccine Safety
Immunization Requirements
Flu Resources
MOBI-KS
|
